Unit of Clinical Pharmacology, Department of Preclinical-Sciences LITA-Vialba, L. Sacco University Hospital, Università di Milano, Milan, Italy.
Oncologist. 2009 Dec;14(12):1201-4. doi: 10.1634/theoncologist.2009-0118. Epub 2009 Dec 4.
Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.
在此，我们报告了一例发生在一名 61 岁女性身上的水疱性皮炎，她在开始接受厄洛替尼治疗 IV 期肺腺癌伴垂体水平转移后 5 天出现该疾病。皮肤反应是表皮生长因子受体酪氨酸激酶（EGFR-TK）抑制剂最常见的药物不良反应（ADR），而痤疮样皮疹是接受厄洛替尼治疗的患者中最常报告的 ADR。据我们所知，这是首例由厄洛替尼引起的水疱性皮炎。本报告强调了需要在 EGFR-TK 抑制剂皮肤毒性领域开展更多的研究。
